Enhancing multi-user nucleic acid research capabilities through acquisition of a high-throughput oligonucleotide synthesizer
Active Grant Awarded
- Award ID
- S15OD042561
- Recipient
-
Carnegie-Mellon University UEI U3NKNFLNQ613
- Awarding agency
-
Aggregate Financial Assistance Data
National Institutes of Health, Department of Health and Human Services
- Obligated
- $349,500
Award facts
- Assistance listing
- 93.351 Research Infrastructure Programs
- Completion date 25% complete
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- Pittsburgh, PA 15213, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health Office of the Director awarded Carnegie-Mellon University $349,500 on August 18, 2026, under Assistance Listing 93.351, Research Infrastructure Programs, to acquire a high-throughput oligonucleotide synthesizer. The award funds a Sierra Biosystems Shasta Oligonucleotide Synthesizer System that will transform CMU's Center for Molecular Analysis into the Center for Nucleic Acids Synthesis and Molecular Analysis. The system provides in-house synthesis of RNA and chemically modified antisense oligonucleotides (ASOs) for CMU research groups and the broader Pittsburgh region, with 24 amidite positions and 8 reagent positions, synthesis from individual sequences up to high-throughput 296-sequence runs, and integrated cascade cleavage/deprotection and Palisade purification modules for automated screening workflows. The stated research uses include NIH-funded work in cancer therapeutics, neurodegenerative diseases, drug delivery, and rare disease therapeutics, with representative users including the Zhang Laboratory (telomere targeting) and the Henninger Laboratory (acute myeloid leukemia). The period of performance runs from the August 18, 2026 award date through August 31, 2027, with place of performance in Pittsburgh, Pennsylvania 15213. The Office of Research Infrastructure Programs, a program office within NIH's Division of Program Coordination, Planning, and Strategic Initiatives, administers the program. The source names no sub-recipients for this award.
Description
- Abstract
- Carnegie mellon university (CMU) requests $349,500 to acquire a sierra biosystems shasta oligonucleotide synthesizer system to establish critical nucleic acid synthesis infrastructure supporting NIH-funded research programs. Multiple research groups at CMU, the center for nucleic acids science & technology (CNAST) community, and the broader pittsburgh region currently spend hundreds of thousands annually on oligonucleotide synthesis. While commercial DNA synthesis is accessible, RNA and chemicallymodified anti-sense oligonucleotides (ASOS) with specialized modifications cost $200-500 per sequence and upwards of $10,000 per 96-well plate, severely limiting academic research and screening capabilities. In-house synthesis reduces costs by 90% while providing access to modifications unavailable through commercial providers. There is only one 17-year-old MERMADE4 functional in the region. The shasta synthesizer will transform CMU's center for molecular analysis (CMA) into the center for nucleic acids synthesis and molecular analysis. The requested system features 24 amidite positions plus 8 reagent positions, making possible synthesis from individual sequences to high-throughput 2×96 synthesis. Its multi-protocol capability enables parallel synthesis of sequences with varied modifications. The integrated cascade cleavage/deprotection and palisade purification modules, unavailable on mermade systems, provide complete automated workflow particularly for plates in high-throughput screening studies. This equipment supports NIH-funded research in cancer therapeutics, neurodegenerative diseases, drug delivery, and rare disease therapeutics. Representative users include: zhang laboratory (telomere targeting requiring specialized ASOS and fish probes); henninger laboratory (acute myeloid leukemia, requiring 50100 ASO variants per target); DAS laboratory (engineered exosomes and RNA polymer hybrids that use custom amidites); whitehead laboratory (lipid nanoparticle delivery for type I diabetes). The synthesizer will enable industry collaborations including a partnership with LA jolla labs, integrating their open-source RNA therapeutic design platform with the CMU facility for rare disease therapeutic development. CMU commits to funding two years of service contracts ($49,025) following the first-year warranty, with fiveyear financial backup guarantee. The requested system will use the existing CMA recharge center financial infrastructure. Regional use by CNAST members and university of pittsburgh researchers, combined with LA jolla labs partnership directing customers to the facility, ensures sustainable utilization beyond CMU. Educational integration through the MS in nucleic acids science, technology and medicine program provides an additional user base. This infrastructure positions CMU as the regional hub for advanced nucleic acid synthesis.
Quick answers
Who received award S15OD042561?
S15OD042561 was awarded to Carnegie-Mellon University by Aggregate Financial Assistance Data (National Institutes of Health) on August 18, 2026.
How much is award S15OD042561 worth?
$349,500 has been obligated on S15OD042561.
Which agency awarded S15OD042561?
Aggregate Financial Assistance Data (National Institutes of Health) awarded S15OD042561, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award